Daidzein inhibits choriocarcinoma proliferation by arresting cell cycle at G1 phase through suppressing ERK pathway \textit{in vitro} and \textit{in vivo}

WEI ZHENG\textsuperscript{1}, RONG SUN\textsuperscript{2}, LEI YANG\textsuperscript{1}, XIANLING ZENG\textsuperscript{1}, YAN XUE\textsuperscript{1} and RUIFANG AN\textsuperscript{1}

\textsuperscript{1}Department of Gynecology and Obstetrics, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061; \textsuperscript{2}Obstetrics and Gynecology Hospital, Fudan University, Shanghai 200012, P.R. China

Received March 23, 2017; Accepted August 17, 2017

DOI: 10.3892/or.2017.5928

Abstract. Choriocarcinoma is a highly malignant tumor arising from abnormal gestational trophoblast proliferation. Although chemotherapy has dramatically improved the prognosis, there are still some patients who become drug-resistant or relapse. Daidzein has garnered interest in its antitumor activity especially in proliferation inhibition. However, few reports exist on daidzein effect in growth of choriocarcinoma. Therefore, in this study, we performed \textit{in vitro} and \textit{in vivo} experiment in JAR and JEG-3 to investigate the effect of daidzein in proliferation of choriocarcinoma. Daidzein inhibited cell growth in a time- and dose-dependent way. Cell cycle was arrested at G1 phase and expression of cyclin D1, c-myc, PCNA was reduced while p21 was upregulated during daidzein treatment. At the same time, the expression of p-ERK was downregulated and translocation into nuclear afterwards was also inhibited. Moreover, ERK agonist ceramide C6 abolished daidzein's effects on cell proliferation. Besides, \textit{in vivo} experiment also showed daidzein's anti-proliferation function as xenografts growth was inhibited and expressions of c-myc, PCNA and p-ERK were suppressed. In conclusion, results in our study demonstrate daidzein can inhibit choriocarcinoma cell proliferation \textit{in vitro} and \textit{in vivo}; underlying mechanism behind the inhibitory effects may probably be suppressing ERK pathway and afterwards arresting cell cycle at G1 phase.

Introduction

Gestational trophoblastic disease is a spectrum of trophoblast abnormal proliferation (1), among which choriocarcinoma is the most malignant one tending to spread to lung, liver and/or brain. Though most choriocarcinoma occurs after a complete mole, it may also be secondary to any normal or abnormal pregnancy, including partial mole, term pregnancy, induced/spontaneous abortion, premature delivery and stillbirth (2). However, ~25% of gestational trophoblastic tumors will be resistant to, or will relapse after initial chemotherapy (3,4). Also, in development of gestational trophoblastic disease, excess proliferation is an important clue and is related with outcome of treatment (5,6). Therefore, we are wondering if there is an alternative medicine which may inhibit trophoblastic cell proliferation and improve the curative rate of choriocarcinoma.

Cell proliferation is regulated by positive and negative cell cycle regulatory factors. Cyclin-dependent kinases (CDKs) are the key factors forming CDKs/cyclins complexes (such as CDK4/cyclin D1), while CDK inhibitors (CKIs), such as p21 and p15, are negative regulators acting as the brakes of the cell cycle transition by obstructing the formation of CDK/cyclin complexes (7,8). Activation of CDK/cyclins is required for cell cycle progression through the G1/S checkpoint. Proliferation nuclear antigen (PCNA), associated with DNA synthesis, functions in the cell cycle progression from early G1 to S phase, and its function is inhibited when p21 binds to it (9). c-myc positively regulates the expression and/or activity of cyclins (D1, D2, E and A), CDK2/CDK4, and additionally suppresses CDKIs such as p15, p21 and p27 (10). Therefore, these proteins are often used to indicate the interference on the cell cycle. Also, arresting cell cycle in G1 phase or G2/M phase is one of the mechanisms used by anticancer medicines.

Cellular proliferation is strongly regulated by mitogen-activated protein kinase (MAPK), including extracellular signal-regulated kinase 1/2 (ERK1/2), e-Jun N-terminal kinase (JNK), and p38 MAPK, in a variety of cell types. The ERK1/2 signaling pathway, activated by phosphorylation and subsequent nuclear translocation, has been implicated as a regulator of cell cycle arrest (11,12). Also, ERK signal pathway is involved in trophoblast cell proliferation and invasion (13,14).

Recently, the antitumor effects of ingredients from diet have been paid attention to because of their accessibility and security. Daidzein belongs to the isoflavones family, one of the most commonly ingested and most intensely studied type of phytoestrogen, often found in nuts, fruits, soybeans, and...
soy-based products (15). Previously, daidzein garnered interest in its antitumor activity especially in proliferation inhibition and apoptosis induction. Daidzein induces apoptosis in prostate cancer cells (LnCap and PC3) (16), and its metabolite inhibits prostate cancer growth in vitro and in vivo (17). In breast cancer, daidzein shows antiproliferation activity, causing cell cycle arrest at the G1 and G2/M phases and its metabolite enhance tamoxifen's caspase-mediated apoptosis induction (18,19). Daidzein also plays its antitumor role in colon cancer, arresting cell cycle at G0/G1 phase (20), as well as other cancers such as cervical cancer, melanoma, hepatic cancer and gastric carcinoma effecting proliferation and/or apoptosis (21-24). As to trophoblast cells, Jeschke et al found a significant decrease of HCG production in daidzein-treated trophoblast cells in a concentration-dependent way (25). However, scarce information on daidzein effect in growth of choriocarcinoma is available.

Moreover, daidzein has a close relationship with ERK. Soy isoflavones decreases the expression causing cell cycle arrest and upregulation of p21 in colon adenocarcinoma (26). Daidzein suppresses phosphorylation levels of ERK when exerting antitumor activity against bladder cancer cells (27). Also, its metabolites are able to inhibit the activation of ERK (28,29).

We hypothesized that daidzein can inhibit choriocarcinoma cell proliferation by arresting the cell cycle, and this may due to the suppression of expression of ERK pathway.

Materials and methods

Cell culture. Choriocarcinoma cell lines JAR and JEG-3 obtained from American Type Culture Collection (Manassas, VA, USA) were cultured in DMEM medium with 10% fetal bovine serum at 37˚C with 5% CO2. ERK was activated by 10 µM concentration of ceramide C6 (C-C6; Santa Cruz Biotechnology, Santa Cruz, CA, USA), added 24 h after daidzein treatment for another 24 h. MTT assay. Growth rates of cells were measured by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma, St. Louis, MO, USA) assay. The absorbance was measured at 490 nm using a universal microplate reader (Model ELx800; BioTek Instruments, Inc., Winooski, VT, USA).

Colony formation assay. JAR and JEG-3 cells were seeded onto 6-well plates at a density of 1,000 cells per well. After 14 days of culture, cells were washed with PBS, fixed with 4% paraformaldehyde, and subsequently stained with 0.1% crystal violet solutions.

Cell cycle analysis. Cells with 60-80% confluence were trypsinized, washed with cold PBS, resuspended with cold 70% ethanol then stored at -20˚C overnight. Before subjected to flow cytometry analysis, ethanol was removed and pellet cells were washed with cold PBS twice, cells were resuspended in PBS with 0.5 µg/ml RNase and 50 µg/ml propidium iodide and incubated at room temperature in the dark for 30 min. Then cell samples were analyzed in a FACSCalibur flow cytometer (Becton-Dickinson, San Jose, CA, USA) and CellQuest software.

Western blot analysis. Cells were washed once with cold PBS and lysed in RIPA buffer (50 mM Tris pH 8.0, 150 mM NaCl, 0.1% SDS, 1% NP-40, and 0.5% sodium deoxycholate) containing protease inhibitors. Approximately 20 µg of protein was separated with 8-12% SDS-PAGE gel and blotted onto nitrocellulose membranes. Then membranes were blocked with 5% skim milk at room temperature for 1 h and then incubated with primary antibodies against β-actin (Abcam, Cambridge, UK), c-myc (Abcam), PCNA (Santa Cruz), cyclin D1 (Santa Cruz), p21 (Cell Signaling Technology, MA, USA), ERK (Abcam) and p-ERK (Abcam) at 4˚C overnight, followed by TBST wash and 1-h incubation with HRP-conjugated secondary antibodies at room temperature. Protein bands were visualized by a Molecular Imager ChemiDoc XRS System (Bio-Rad Laboratories, Hercules, CA, USA).

Immunofluorescence microscopy. Cells were fixed in 4% paraformaldehyde in PBS for 15 min, and then permeabilized with 0.1% Triton X-100 for 15 min and blocked in 1% BSA for 1 h. Cells were sequentially incubated with primary antibody (p-ERK; 1:100 in 1% BSA) at 4˚C overnight, followed by Alexa Fluor 488 second antibody (1:150 in 1% BSA) for 1 h and DAPI for 5 min. Slides were analyzed and photographed by Olympus BX51 Microscope (Olympus, Tokyo, Japan).

Xenograft tumor model. Fifteen mice were randomly divided into three groups depending on different gavage components: negative control group (edible oil only), low dose group (10 mg/kg body weight/day of daidzein dissolved in oil) and high dose group (20 mg/kg body weight/day of daidzein dissolved in oil). For tumorigenesis assay in nude mice, 5x106 JEG-3 (considering JEG-3 more easily formed subcutaneous xenografts than JAR when performing pre-experiment) were injected subcutaneously into left sides of the flank region after 1 week daily gavage feeding. Three weeks after subcutaneous injection with JEG-3 (4 weeks after daily gavage with/uniformer different concentration of daidzein), the mice were sacrificed, then xenograft tumors were harvested, weighed and fixed with 4% paraformaldehyde. Animal care and protocols were in accordance with the guidelines of the Institutional Animal Care and Use Committee of Xi’an Jiaotong University.

Immunohistochemistry. Tumor sections of nude mouse xenografts were studied by immunohistochemistry (IHC) assay using EnVision™ System (Dako, Carpinteria, CA, USA). Primary antibodies used in IHC were c-myc (Abcam), PCNA (Santa Cruz), p-ERK (Abcam). Staining signals were photographed using an Olympus BX51 microscope (Olympus, Tokyo, Japan).

Statistical analysis. All experiments were repeated at least three times. Statistical analysis was carried out using the SPSS 19.0 statistical software package (SPSS, Inc., Chicago, IL, USA) was used to analyze differences between two groups (Student’s t-test) and p-values <0.05 were regarded as statistically significant.
Results

Daidzein reduces cell viability in choriocarcinoma cell lines. Using MTT assay, we investigated the viability inhibition effect of daidzein in CC cell lines JAR and JEG-3. Both cell lines were treated with daidzein at concentration of 12.5, 25, 50, 100, 200 and 400 µM. The results showed that daidzein had a concentration- and time-dependent effect on JAR cell viability. With the increasing of concentration or time of treatment with daidzein, the viability decreased. Also, the IC₅₀ at 24, 48 and 72 h were 101.60, 92.56 and 87.73 µM, respectively (Fig. 1A). Similar effect were seen in JEG-3, while the IC₅₀ was 103.10, 94.14 and 68.82 µM, respectively (Fig. 1B).

Daidzein treatment inhibits proliferation of choriocarcinoma cells. In order to determine whether the cell viability reduction is due to proliferation inhibition, we performed colony formation assay on both cell types with daidzein treatment. The colony-forming capacity of JAR and JEG-3 decreased as the concentration of daidzein increased. While 25 µM daidzein seemed not to change much, treatment with 50 and 100 µM daidzein markedly suppressed proliferation. However, when the concentration reached 200 µM, colonies hardly formed (Fig. 2A and B).

Cell cycle is arrested in G1 phase when treated with daidzein. Cell proliferation inhibition is usually associated with cell cycle arresting at a specific stage. To examine if daidzein causes cell cycle arrest, we performed fluorescence-activated cell sorting (FACS) analysis. In the asynchronized steady state, the percentage of proportion of G1 phase cells was greater after treated with daidzein. In JAR cells, G1 phase
percentage of proportion was 61.66, 65.38 and 72.64% treated with 25, 50 and 100 µM, respectively, while it was only 48.02 without (Fig. 2C). As to JEG-3 cells, daidzein increased G1 phase percentage from 50.85% (0 µM) to 56.34, 60.00 and 61.07% (25, 50 and 100 µM, respectively, Fig. 2D). Then we detected the expression of G1 phase related proteins (c-myc, PCNA and cyclin D1) and p21, one of CDKIs family, by western blot analysis. The expression levels of c-myc, PCNA and cyclin D1 were decreased significantly, and the decrease was greater with the increase of concentration (p<0.05, respectively). On the contrary, the expression level of p21 increased, and the differences were also significant (p<0.05, respectively, fig. 2E and F). These results suggest that choriocarcinoma cells are arrested at the G1 phase by daidzein.

**Daidzein suppresses ERK1/2 phosphorylation and p-ERK1/2 nuclear translocation.** When detecting expression of cell cycle associated protein, we also found that daidzein suppressed ERK1/2 by reducing phosphorylation, which suggested ERK1/2 might participate in daidzein proliferation inhibition capacity (p<0.05, respectively, Fig. 3A and B). As known, ERK1/2 is involved in phosphorylation and subsequent nuclear translocation, so we wondered whether daidzein might also affect nuclear translocation of ERK1/2. Therefore, we undertook to examine whether daidzein influenced this process by using immunofluorescence staining (IF), and the results showed that compared with DMSO, phospho-ERK1/2 translocated into the nucleus less after daidzein treatment (Fig. 3C and D) in both cell-lines. Taken together, our results suggested daidzein could inhibit ERK1/2 phosphorylation and p-ERK1/2 nuclear translocation.

**Daidzein-caused proliferation inhibition was abolished by C-C6.** The changes of phosphorylation and translocation of ERK1/2 were obtained during daidzein's proliferation inhibition as described above, thus we hypothesized ERK1/2 involved in daidzein-caused choriocarcinoma cell proliferation suppression. Ceramide C6 is ERK pathway agonist, and could significantly increase phosphorylation of ERK which was inhibited by daidzein in both cell lines (p<0.05, respectively, Fig. 4A and B). At the same time, colony formation assay showed that C-C6 obviously increased the amount of cell colonies which were decreased by daidzein (Fig. 4C and D). Compared to daidzein only, C-C6 decreased G1 phase percentage from 74.56 to 63.02 and 60.75 to 54.02 in JAR and JEG-3, respectively on the basis of daidzein (Fig. 4E and F). Besides, C-C6 also abolished daidzein's increase on protein expressions of c-myc, PCNA and cyclin D1 and decreased p21 (fig. 4G and H). In summary, daidzein's proliferation inhibition on choriocarcinoma cells can be abolished by ERK pathway agonist C-C6, therefore, we consider that ERK participated in this process.

**Daidzein inhibits choriocarcinoma growth in vivo.** To determine whether daidzein's anti-proliferation activity in vitro could be extended in vivo, subcutaneous xenograft model was introduced in this study. Average weights of tumors in three groups showed negative correlation with daidzein concentration (Fig. 5A). The low dose group was lighter than that of control group, and weight in high dose group was even lighter than low dose group (p<0.05, Fig. 5B). We then stained c-myc, PCNA and p-ERK expression in these JEG-3 xenograft tissues using IHC assays (Fig. 5C). The
reduced c-myc and PCNA expression was accompanied with less p-ERK staining in low dose group and even less in high dose group than control. The IHC scores of c-myc, PCNA and p-ERK in control group were 10.60±1.95, 8.20±2.49 and 7.40±3.13, those in low dose group were 5.60±1.67, 4.20±1.10 and 3.60±1.82, while those in high dose group were 2.60±1.95, 2.00±1.12 and 1.60±1.42.

Figure 4. The influence of ERK agonist C-C6 on proliferation inhibiting ability of daidzein. (A and B) Change of p-ERK expression by C-C6 in presence/absence of daidzein in JAR and JEG-3. (C and D) Colony formation of JAR and JEG-3 treated by C-C6 with/without daidzein. (E and F) Cell cycle distribution of JAR and JEG-3 treated by C-C6 combined with daidzein or not. (G and H) Western blotting and the quantification of proliferation associating markers in appearance of daidzein and C-C6, single or combined. Dd stands for daidzein. Compared with 0 µM, *p<0.05, **p<0.01. Daidzein combined C-C6 compared to daidzein only, *p<0.05, **p<0.01.

Figure 5. Daidzein effect on choriocarcinoma growth in vivo. (A) Subcutaneous xenografts of JEG-3 three weeks after subcutaneous injection (4 weeks after daily gavage with/without different concentration of daidzein). (B) Tumor weight of three groups. (C) Immunohistochemistry of tumor sections stained with c-myc, PCNA and p-ERK. (D) The IHC scores of these markers among three groups. Bar, 50 µm. Compared with NC group, *p<0.05, **p<0.01.
correlation with p-ERK (Fig. 5D). These data suggested that daidzein could also inhibit choriocarcinoma growth in vivo by downregulating c-myc and PCNA, and this process was probably mediated by p-ERK.

Discussion

Choriocarcinoma is a highly malignant tumor arising from abnormal gestational trophoblasts proliferation. The use of chemotherapy has dramatically improved the prognosis of these lesions. However, despite serious side effect of chemotherapy, there are still some patients who become drug-resistant or relapse, and may finally die of liver or brain metastasis (30). Thus, it is meaningful to investigate inhibition of choriocarcinoma cell proliferation without increasing the patients side-effect burden.

Daidzein is a member of isoflavones, and is easily gained from food especially soybeans or soy-based product (31-33). Daidzein has been studied in many tumors due to its anti-proliferation action (16,21,24). In choriocarcinoma, daidzein shows its regulatory function in hCG production (25). In this study, we performed in vitro and in vivo experiments to examine the effects of daidzein on proliferation of choriocarcinoma and explore the underlying mechanism. Also, our results demonstrate an antiproliferation action of daidzein on choriocarcinoma.

Daidzein has shown its antiproliferation function in various cells by cell cycle arrest. Daidzein can induce accumulation of cells in G1 phase in human melanoma cells (34), and cause cell cycle arrest at G1 and G2/M phase in human breast cancer MCF-7 and MDA-MB-453 cells (19). Daidzein can also block G1 phase cell cycle progression of Swiss 3T3, an immortal line of fibroblast-like cells (35). In this study, we found that daidzein inhibited choriocarcinoma cell-lines JAR and JEG-3 growth rate and clone formation in a time- and concentration-dependent manner, during which cell cycle was arrested at G1 phase in both cell types detected by flow cytometer. At the same time, the expression of cyclin D1 was reduced by daidzein, as well as c-myc and PCNA, which can also help cell cycle progression. While the expression of p21, one of CKDs, increased. These results strongly support that daidzein can inhibit proliferation by cell cycle arrest at G1 phase.

ERK1/2 is one of MAPK family members involved in proliferation and other cell activities (36-38). Daidzein has been reported to suppress ERK1/2 activation during its antiproliferation function in tumors (26,27). In this study, during daidzein treatment, the expression of phospho-ERK1/2 was reduced, determined by western blotting. Immunofluorescence staining showed that p-ERK translocation into the nucleus was obstructed as more p-ERK stayed in the cytoplasm suggesting that daidzein suppress ERK activation by inhibiting phosphorylation and translocation into the nucleus. Then we used ERK agonist C-C6 to confirm whether ERK was involved in daidzein proliferation in JAR and JEG-3. Unsurprisingly, compared with daidzein treatment only, C-C6 increased colony formation of both cells, and also decreased G1 phase percentage. At the same time, cyclin D1, c-myc and PCNA reduction and p21 increase were weakened or offset. Collectively, daidzein inhibits choriocarcinoma cells proliferation by cell cycle arrest at G1 phase via ERK pathway in vitro.

Furthermore, we performed experiments in vivo to see if this proliferation inhibition could be still effective in vivo. It has been reported that daidzein and its metabolite can cause tumor growth inhibition in other tumors in vivo (39-41). Similar effect was also obtained in our study, as daidzein also inhibited subcutaneous xenograft growth. Average tumor weight in control group was much higher than that of low dose group, while weight of high dose group was even lower. Then IHC scores of c-myc, PCNA and p-ERK in these tumor tissue slides showed similar tendency with western blotting in vitro experiment: daidzein addition decrease p-ERK expression in xenografts as well as c-myc and PCNA, and the higher dose we gave, the more effect we gained.

In conclusion, we demonstrated that daidzein can inhibit choriocarcinoma cell proliferation in vitro and in vivo, and underlying mechanism behind the inhibitory effects may probably be suppressing ERK pathway and afterwards arresting cell cycle at G1 phase. Our findings provide new insight into the application of daidzein in treatment of choriocarcinoma to improve therapy efficiency.

Acknowledgements

This study was supported by the National Natural Science Foundation of China (no. 81172489).

References


